Sass Compiling Error
/nas/content/live/kymeratx/wp-content/themes/kymera/nas/content/live/kymeratx/wp-content/plugins/wp-scss/cache/ 
"File Permission Error, permission denied. Please make the cache directory writable."
/nas/content/live/kymeratx/wp-content/themes/kymera/nas/content/live/kymeratx/wp-content/plugins/wp-scss/cache/ 
"File Permission Error, permission denied. Please make the cache directory writable."
/nas/content/live/kymeratx/wp-content/themes/kymera/nas/content/live/kymeratx/wp-content/plugins/wp-scss/cache/ 
"File Permission Error, permission denied. Please make the cache directory writable."
Discovery and characterization of IRAKIMiDs: degraders targeting both IRAK4 and IMiD substrates for oncology indications | Kymera Therapeutics Discovery and characterization of IRAKIMiDs: degraders targeting both IRAK4 and IMiD substrates for oncology indications - Kymera Therapeutics
Back to All Resources

Discovery and characterization of IRAKIMiDs: degraders targeting both IRAK4 and IMiD substrates for oncology indications

June 7, 2022

Targeting protein degradation 3 – from discovery to the clinic (TPD3)

TPD3 Thumbnail
View Presentation
Area of Focus
Oncology Targeted Protein Degradation
Programs
Other
Indications
Other
Development Stage
Pre-clinical Data
Share
LinkedInXFacebookEmailCopy Link

You may also be interested in these resources

August 24, 2022
Discovery and characterization of potent degraders of IRAK4 and IMiD substrates for oncology indications
ACS Fall 2022
Other
View Resource
June 26, 2022
Discovery of IRAKIMiDs: Dual-Mechanism Degraders Targeting IRAK4 and IMiDSubstrates for Oncology
37th ACS National Medicinal Chemistry Symposium
Other
View Resource